Bellsonica Auto Component India v. ACIT (2026): a transfer-pricing royalty adjustment must be capped at the rate the CBDT accepted under the assessee's APA

Bellsonica Auto Component India Pvt. Ltd. v. ACIT is a transfer-pricing decision of the Income Tax Appellate Tribunal, Delhi Bench, delivered by S. Rifaur Rahman, Accountant Member, and Vimal Kumar, Judicial Member. The dispute is a familiar one in cross-border tax: an Indian subsidiary pays its overseas associated enterprise for the use of technology, and the Transfer Pricing Officer (TPO) proposes a large downward adjustment on the footing that the payment exceeds what unrelated parties would have agreed. What makes this case worth a digest is the lever the Tribunal used to discipline that adjustment — a Unilateral Advance Pricing Agreement (UAPA) the assessee had concluded with the Central Board of Direct Taxes (CBDT), which had accepted a consolidated royalty-and-technical-fee rate of 1.9% of net sales.

The facts in brief

Bellsonica Auto Component India is an Indian company in the automotive-components sector. For the assessment year 2014-15, it had made payments to its associated enterprise on account of royalty and fees for technical services (FTS) — the kind of intra-group payment that, because it flows between related parties, is subject to the arm's-length scrutiny of India's transfer-pricing regime.

The matter was referred to the Transfer Pricing Officer under Section 92CA(1) of the Income-tax Act, 1961. The TPO took the view that the royalty and technical-fee payments exceeded the arm's-length price and proposed an adjustment of roughly Rs 8.47 crore in respect of those payments. Against this, the assessee had returned a loss of about Rs 1.68 crore, so the proposed adjustment was substantial relative to the company's declared position.

The crucial additional fact was that the assessee had, in the meantime, entered into a Unilateral Advance Pricing Agreement with the CBDT — concluded on 29 November 2022 — under which the CBDT accepted a consolidated rate of 1.9% of net sales for the royalty and fees-for-technical-services payments. The assessee's case was, in essence, that the State's own pricing machinery had already examined and accepted a rate, and that the TPO could not insist on something materially harsher.

The question

The question for the Tribunal was how a concluded Advance Pricing Agreement should bear on a transfer-pricing adjustment for a year covered by — or governed by the same facts as — that agreement. An APA is a mechanism by which a taxpayer and the tax authority agree, in advance, on the methodology for determining the arm's-length price of specified international transactions. The CBDT's acceptance of the 1.9% rate was therefore not a litigant's self-serving estimate but a rate vetted and accepted by the very authority charged with policing transfer pricing.

If that is so, can the TPO nonetheless propose an adjustment that ignores the CBDT-accepted rate and substitutes a higher figure? Or does the discipline of the APA — the arm's-length rate the State itself has accepted — operate to cap the permissible adjustment?

What the Tribunal held

The Tribunal held that the TPO's adjustment was excessive and could not stand to the extent it exceeded the rate accepted by the CBDT. It set aside the impugned addition and directed the Assessing Officer to cap the royalty and technical-fee rate at the figure the CBDT had accepted under the Unilateral Advance Pricing Agreement — that is, at 1.9% of net sales.

In reaching that conclusion, the Tribunal treated the methodology and rate embodied in a concluded APA as carrying considerable persuasive weight for determining the arm's-length price, referring to the decision in Ranbaxy Laboratories Ltd. The reasoning was that an agreement entered into by the CBDT, after it has examined the relevant aspects of the assessee's transactions, deserves real respect — it represents a considered determination by the tax administration itself, not merely an assertion by the taxpayer.

Analysis

The interest of Bellsonica lies in the relationship it draws between two arms of the same transfer-pricing regime: the Section 92CA reference to the TPO on the one hand, and the Advance Pricing Agreement machinery (introduced into the Act through Section 92CC) on the other. Both are instruments for arriving at the arm's-length price of an international transaction. The APA, however, is the more deliberate of the two — it is the product of a forward-looking agreement between the taxpayer and the CBDT, reached after scrutiny and negotiation, rather than an adjustment imposed in the course of an assessment.

The Tribunal's move is to let the more considered instrument discipline the less considered one. Once the CBDT has accepted a rate of 1.9% of net sales for the very category of payments in dispute, it becomes difficult to justify a TPO adjustment that proceeds as though no such acceptance existed. The rate the State has itself accepted operates as a ceiling on what the same State's transfer-pricing officer can extract for substantially the same transactions. That is why the Tribunal characterised the higher addition as "excessive" rather than simply wrong on method: the existence of the APA supplies an authoritative benchmark against which the excess can be measured.

The reliance on Ranbaxy Laboratories Ltd. situates the holding within an existing line of reasoning that a concluded APA possesses persuasive value for arm's-length determination. The logic is consistency-based. It would be incoherent for the tax administration to accept a rate through one of its own processes and then, through another, treat a materially higher figure as the true arm's-length price. The taxpayer who has gone through the APA process — and obtained the CBDT's acceptance — is entitled to expect that acceptance to count.

A note of caution on scope is warranted. The decision turns on the existence of a CBDT-accepted rate for the relevant category of payments and on the Tribunal's reading of the APA as governing the position; the precise mechanics of how the 1.9% rate maps onto the disputed year (the APA was concluded on 29 November 2022, and the year in issue is 2014-15) are best confirmed from the full text of the order rather than from the holding alone. What the Tribunal squarely decided is that the adjustment had to be brought down to the CBDT-accepted rate.

Why it matters

For multinationals with Indian operations, Bellsonica is a useful illustration of the practical value of an Advance Pricing Agreement beyond the years it formally covers. An APA is often pursued for certainty going forward; this decision shows it can also be deployed defensively, as a benchmark that caps a TPO adjustment which strays above the rate the CBDT has accepted. The taxpayer who has secured the administration's acceptance of a rate carries a powerful argument that any higher adjustment for the same kind of transaction is, on its face, excessive.

For the revenue, the lesson is one of internal consistency. A transfer-pricing adjustment that ignores a rate the CBDT itself has accepted invites exactly the result reached here — a direction to cap the adjustment at the accepted figure. And for practitioners, Bellsonica reinforces a line of authority, anchored in Ranbaxy Laboratories Ltd., that a concluded APA carries persuasive weight in fixing the arm's-length price, and that the methodology the CBDT has accepted should guide — and in an appropriate case constrain — the determination of an adjustment under Section 92C.

Related on Valkya

• PCIT v. BorgWarner — emissions, DRP and transfer pricing
• Reckitt Benckiser v. ACIT — the bright-line test and AMP expenditure

Sources

• Taxscan, "UAPA Principles Must Guide Transfer Pricing Analysis: ITAT Restricts Royalty and FTS Adjustment to CBDT-Accepted Rates" — taxscan.in